Clinical Trial Update: A Study of Evorpacept (ALX148) With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02) [Phase 1]

View source ↗

Summary

This document reports the termination of the Phase 1 ASPEN-02 trial evaluating evorpacept (ALX148) in combination with azacitidine for higher-risk myelodysplast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Evorpacept (ALX148) (evorpacept)

Snippet

Sponsor: ALX Oncology Inc. | Conditions: Higher Risk Myelodysplastic Syndromes | Phase 1 | Status: TERMINATED